NCT05029882 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05029882
Title	Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
Recruitment	Active, not recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	AbbVie
Indications	colorectal cancer lung non-small cell carcinoma renal cell carcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma Advanced Solid Tumor
Therapies	Bevacizumab + Telisotuzumab adizutecan Telisotuzumab adizutecan Bevacizumab + Trifluridine-tipiracil hydrochloride
Age Groups:	adult \| senior
Covered Countries	USA \| POL \| ISR \| FRA \| ESP \| AUS

Additional content available in CKB BOOST